Copyright
©The Author(s) 2019.
World J Hepatol. Feb 27, 2019; 11(2): 173-185
Published online Feb 27, 2019. doi: 10.4254/wjh.v11.i2.173
Published online Feb 27, 2019. doi: 10.4254/wjh.v11.i2.173
Model features | Advantages | Disadvantages | |
Type A Model. Encephalopathy associated with acute liver failure | Type A models have been developed by exclusion (anhepatic models), partial removal of the liver or from the administration of a hepatotoxins | Anhepatic model: The course of HE is relatively rapid. Applied to studies of brain metabolism, neurotransmission abnormalities, gene expression and brain inflammation in ALF. The model responds to hypothermia, ammonia-lowering agents and anti-inflammatory drugs; Hepatotoxic model: Different hepatotoxins could be used to create Type A models. Generally, these models produce hypothermia, hypoglycemia and other systemic complications; Thioacetamide: Model with good repeatability, easy operation, and high similarity to human HE; Acetaminophen: Easy preparation, low price and dose-dependence; D-galactosamine: Good repeatability. Simulates the pathophysiological changes of acute liver failure. Shows manifestations of liver injury that are similar to viral hepatic failure | Anhepatic model: Neither procedure could lead to a potential recovery. The surgical procedure causes great trauma to the animal. Absence of injured or necrotic hepatic cells. The toxic substances and inflammatory mediators present in the injured liver are not perfused into the blood circulation; Partial hepatectomy: The surgery is difficult to control. Severe hypoglycemia leads to death; Hepatotoxic model: Each of these toxins could produce hepatitis with variable pathological nature. Animal-to-animal variations lead to a lack of reproducibility. Some hepatotoxins show extrahepatic toxicity; Acetaminophen: Poor reproducibility. Shows side effects in kidneys and other organs; D-galactosamine: High cost, short survival time and poor stability |
Type B Model. Encephalopathy associated with portosystemic bypass without liver disease | Type B models have been developed by portosystemic shunting (portacaval anastomosis, congenital portacaval shunts, graded portal vein stenosis, and biliary duct ligation). Different HE aspects could be assessed using different shunt methods and species (pig, dog, rabbit, rat, and mouse) | Portacaval anastomosis: Can better simulate the clinical mild HE phenotypes in different animal models. (Dog) EEG changes and neurological status correlate with ammonia in the plasma; Congenital portacaval shunts: (Dogs) Naturally develop psychomotor dysfunction, reduced hepatic function, and hyperammonemia and are susceptible to high-protein diets; Graded portal vein stenosis: Easy to perform. The surgery may be reversed. (Rat) Provides a Minimal Hepatic Encephalopathy model. (Rat) Develop loss of activity, altered circadian rhythm, hyperammonemia, and altered ammonia/glutamine in the brain | Portacaval anastomosis: Cause severe coma due to hypersensitivity to ammonia. (Rabbit) Portacaval anastomosis may lead to death of animal in most cases. (Rat) Needs high surgical skills to perform; Congenital portacaval shunts: Access to animals with this congenital alteration |
Type C Model. Encephalopathy associated with liver disease | HE associated with cirrhosis and portal hypertension (Type C) is the most common form of HE in patients. At present, there is no appropriate model to study HE that occurs in liver cirrhosis; nevertheless, some models have been developed | Biliary duct ligation: Animals develop liver failure, jaundice, portal hypertension, immune system dysfunction, and bacterial translocation. (Rat) Reproducible model of biliary cirrhosis with the development of hyperammonemia, low-grade encephalopathy, and decreased locomotor activity. (Rat) Bile duct-ligated animals fed with ammonium salts provide a model that reproduces human Alzheimer Type II astrocytosis | No satisfactory Type C animal model induced by alcoholic liver disease or viral hepatitis exists at the present time; Biliary duct ligation: Immune system dysfunction and other diseases may affect the final HE phenotypes. (Rat) Weight loss due to hunger suppression; CCl4: Animal-to-animal variations lead to a lack of reproducibility. Limited neurobehavioral assessment due to the presence of ascites. Possible health damage when a researcher uses this chemical |
Models of acute/chronic hyperammonemia | These models are designed to study the effects of hyperammonemia on brain function without liver dysfunction | Inexpensive and simple to perform. The model shows alterations of multiple neurotransmitter systems in the brain. The model shows impairments in learning and memory | Limited to rats and mice. Time-consuming; not suitable for long-term studies. Lacks liver failure |
Species used | Main findings | |
Surgical models | ||
Hepatic devascularization | Rat, rabbit, pig | Increased AST, hypoglycemia, lethargy and coma |
Hepatectomy | Rat, pig | Increased AST, TNF, PT, NH3, lactate, hypoglycemia, hepatic necrosis |
Pharmacological models | ||
Galactosamine (IP, IV, SC) | Rat, rabbit, guinea pig | Increased AST, PT, NH3, hepatic necrosis |
Acetaminophen (IP, IV, SC, oral) | Rat, dog, pig | Increased AST, NH3, bilirubin, hypoglycemia, metabolic acidosis, centrilobular coagulative necrosis |
Thioacetamide (IP, oral) | Rat | Increased AST, PT, NH3, metabolic acidosis, centrilobular necrosis |
Azoxymethane (IP, SC) | Mouse | Increased AST, NH3 and bilirubin, hepatic necrosis |
Experimental model | Animal species | Biological findings | Clinical Signs |
Portacaval anastomosis | Rats, dog, rabbit, pig | Increased brain ammonia/glutamine | Altered circadian cycle, hypokinesia, reduced memory and learning ability |
Congenital portacaval shunts | Dogs, cats | Hyperammonemia | Hepatic dysfunction, psychomotor dysfunction, motor signs |
Graded portal vein stenosis | Rats | Increased brain ammonia/glutamine | Minimal hepatic encephalopathy, loss of activity, altered circadian cycle |
Carbon tetrachloride (CCl4) | Rats, mice | Generation of free radicals, lipoperoxidation, tissue fibrosis, increased hepatic membrane permeability | Hepatic failure, motor activity dysfunction |
Bile duct ligation | Rats | Bacterial translocation, immune system dysfunction, hyperammonemia | Liver failure, portal hypertension, decreased locomotor activities due to low-grade encephalopathy |
- Citation: Lima LCD, Miranda AS, Ferreira RN, Rachid MA, Simões e Silva AC. Hepatic encephalopathy: Lessons from preclinical studies. World J Hepatol 2019; 11(2): 173-185
- URL: https://www.wjgnet.com/1948-5182/full/v11/i2/173.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i2.173